# Nabla **Source:** https://geo.sig.ai/brands/nabla **Vertical:** Healthcare Tech **Subcategory:** AI Clinical Copilot **Tier:** Emerging **Website:** nabla.com **Last Updated:** 2026-04-14 ## Summary AI clinical copilot. 85K+ clinicians, 130+ organizations. 20M patient interactions/year. Raised $70M Series C. Evolving to Adaptive Agentic Platform. Founded in Paris. ## Company Overview Nabla is a Paris-based clinical AI company founded in 2018 with a mission to reduce the documentation burden that is one of the primary drivers of clinician burnout across health systems globally. The company developed an AI clinical copilot that listens to patient-physician conversations and automatically generates structured clinical notes in the background, allowing clinicians to focus entirely on the patient rather than on documentation. Nabla's core technology applies large language models fine-tuned on medical language and SOAP note structure to produce accurate, editable documentation in real time.\n\nNabla's platform serves more than 85,000 clinicians across 130-plus organizations spanning hospitals, ambulatory practices, and digital health providers. It has facilitated over 20 million patient interactions per year, making it one of the highest-volume ambient AI documentation platforms in the market. The product supports more than 45 medical specialties, with specialty-specific note templates that reflect the distinct documentation requirements of fields ranging from psychiatry to orthopedics. Nabla is evolving its platform toward an Adaptive Agentic architecture, enabling the AI to take actions beyond note-taking — such as ordering follow-ups, drafting referrals, and surfacing clinical decision support.\n\nNabla raised a $70 million Series C to fund US expansion and platform development, following strong adoption in the European market. The company competes in the ambient clinical documentation space alongside Nuance DAX, Suki, and Abridge, but differentiates through its European regulatory expertise, multi-specialty coverage, and its strategic shift toward a full agentic clinical platform. With 20 million annual patient interactions and a clear product roadmap toward autonomous clinical workflow automation, Nabla is well positioned to grow into a broader clinical AI infrastructure role. ## Frequently Asked Questions ### What does Nabla do? AI medical copilot generating clinical notes from consultations with ambient documentation, dictation, and coding. ### How widely is Nabla adopted? 85K+ clinicians across 130+ organizations, 20M patient interactions/year. ### How much has Nabla raised? $70M Series C led by HV Capital. ### What is the Adaptive Agentic Platform? Expansion beyond scribing: proactive EHR actions, automated coding, and multi-setting clinical support. ### How does Nabla's Adaptive Agentic Platform go beyond clinical documentation? Nabla's Adaptive Agentic Platform extends beyond ambient note generation to proactive EHR actions — automatically ordering standard follow-up tests, populating referral letters, submitting prior authorizations, and updating problem lists based on encounter content. The platform learns each clinician's preferences over time, adapting its automation behavior to individual workflows. This evolution from scribing tool to clinical copilot represents Nabla's competitive differentiation from documentation-only tools. ### How does Nabla handle privacy and data security for 20M patient interactions? Nabla operates under HIPAA compliance with BAAs for US healthcare customers, GDPR compliance for European deployments, SOC 2 Type II certification, and encrypted data storage and transmission. Patient audio is processed in real-time and not stored after note generation. Nabla's enterprise contracts include data processing agreements specifying data handling, retention, and deletion policies required by health system security and legal teams. ### What is Nabla's EHR integration approach? Nabla integrates with Epic, Oracle Health, Athenahealth, and other major EHR platforms via SMART on FHIR APIs, enabling direct note insertion into the EHR encounter without copy-paste. The ambient microphone listens during the clinical encounter through the clinician's smartphone or dedicated hardware, processes the conversation, and populates the structured note into the EHR within seconds of the encounter ending. Native EHR integration is a prerequisite for adoption at the 130+ organization scale Nabla has achieved. ### How does Nabla's $70M Series C position it competitively? Nabla's $70M Series C from HV Capital provides expansion capital for US commercial growth to complement its European base of 85K+ clinicians. The European presence gives Nabla clinical validation data and multi-specialty breadth that US-only competitors lack. The funding supports enterprise sales expansion in the US — a larger and higher-value market — while Nabla competes with Nuance DAX, Ambience, and Suki for market share among major US health systems. ## Tags b2b, healthtech, saas --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*